Drug Approval | March 29, 2023
Zydus receives final approval from USFDA for Loperamide Hydrochloride Capsules
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
The company is addressing these observations
Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety
Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation)
Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
Subscribe To Our Newsletter & Stay Updated
